Lakewood-Amedex Biotherapeutics

Q2 FY2026 EarningsQ2 FY26 missed consensus estimates significantly, with a net loss of $3.77M compared to the expected $1.10M. EPS (GAAP) was -$2.75, far below the consensus of -$0.65, primarily driven by a $2.36M non-cash professional service expense related to the Nasdaq listing. While revenue remained at zero as expected for this clinical-stage biotech, total operating expenses surged to $3.79M, exceeding the implied consensus. Management guided that current liquidity, bolstered by the $7.5M Series C financing, will fund operations into Q1 FY27.